FDA 483 - Minaris Regenerative Medicine, LLC - September 29, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Minaris Regenerative Medicine, LLC in Allendale, NJ, a contract manufacturer, revealed significant deficiencies in their quality systems. Observations included a failure to establish adequate written procedures for production and process controls, particularly regarding deviation documentation for LYFGENIA. Additionally, the firm lacked written procedures for handling post-marketing adverse drug experiences and failed to document major equipment in batch production records.
ID · 2e8810f5-aad5-4204-886c-ab4e63c9488b